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Dihydrotanshinone I (DHT) is a natural compound extracted from Salvia miltiorrhiza
Bunge which has been widely used for treating cardiovascular diseases. However, its
role in atherosclerosis remains unclear. In this study, the effect of DHT on atherosclerosis
were investigated using apolipoprotein E-deficient (ApoE−/−) mice and endothelial
cells. In lipopolysaccharide (LPS)-stimulated human umbilical vein endothelial cells
(HUVECs), DHT (10 nM) decreased lectin-like ox-LDL receptor-1 (LOX-1) and NADPH
oxidase 4 (NOX4) expression, reactive oxygen species (ROS) production, NF-κB nuclear
translocation, ox-LDL endocytosis and monocytes adhesion. Silence NOX4 inhibited
LPS-induced LOX-1 expression, NF-κB nuclear translocation, ox-LDL endocytosis and
monocytes adhesion. In ApoE−/− mice fed with an atherogenic diet, DHT (10 and
25 mg kg−1) significantly attenuated atherosclerotic plaque formation, altered serum
lipid profile, decreased oxidative stress and shrunk necrotic core areas. The enhanced
expression of LOX-1, NOX4, and NF-κB in aorta was also dramatically inhibited by DHT.
In conclusion, these results suggested that DHT showed anti-atherosclerotic activity
through inhibition of LOX-1 mediated by NOX4/NF-κB signaling pathways both in vitro
and in vivo. This finding suggested that DHT might be used as a potential vascular
protective candidate for the treatment of atherosclerosis.
Keywords: dihydrotanshinone I, lipopolysaccharide, LOX-1, ROS, atherosclerosis
Abbreviations: AA, antimycin A; All, allopurinol; ApoE−/− mice, apolipoprotein E-deficient mice; CMC-Na,
carboxymethyl cellulose sodium; DCFH2-DA, 5-(6)-carboxy-2′, 7′-dichlor- odihydrofluorescein diacetate; DHE,
dihydroethidium; DHT, dihydrotanshinone I; DPI, diphenyleneiodonium chloride; DPPH, 2, 2-diphenyl-1-picrylhydrazyl;
GSH, glutathione; HCD, high cholesterol diet; HDL-C, HDL cholesterol; H&E, haematoxylin and eosin; HUVECs, human
umbilical vein endothelial cells; ICAM-1, intercellular adhesion molecule-1; LDL-C, LDL cholesterol; LOX, lipoxygenase;
LOX-1, lectin-like oxidized low-density lipoprotein receptor-1; LPS, lipopolysaccharide; MDA, malondialdehyde; MTT, 3-
(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide; NAC, N-acetyl-L-cysteine; NDGA, nordihydroguaiaretic
acid; NOX4, NADPH oxidase 4; N.S, no significant differences; ox-LDL, oxidized low-density lipoprotein; PDTC, pyrrolidine
dithiocarbamate; ROS, reactive oxygen species; Rot, rotenone; SOD, superoxide dismutase; TC, total cholesterol; TG,
triglyceride; TTFA, 2-thenoyltrifluoroacetone; XO, xanthine oxidase.
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INTRODUCTION
Atherosclerosis is considered to be a chronic inflammatory
disease and plays a key role in heart attacks, strokes, and
peripheral vascular diseases (Libby, 2002; Frostegard, 2013). Over
the last decades, atherosclerotic cardiovascular diseases remain
the leading cause of mortality worldwide (Gaziano et al., 2010).
One critical event in the initiation of atherosclerosis is the ox-
LDL uptake, which contributes to the atherosclerotic foam cell
and plaque formation (Steinberg, 1997; Kita et al., 2001). Ox-
LDL uptake is principally mediated by a variety of specific
receptors including SR-A I/II, CD36, SR-BI, etc. (Li and Glass,
2002; Hu et al., 2010). Recently, LOX-1 has been identified as
the main endothelial receptor for ox-LDL (Sawamura et al., 1997;
Chen et al., 2002). LOX-1 is a 50-kD transmembrane protein
highly expressed on macrophages, vascular smooth muscle cells,
and especially endothelial cells, which plays important roles
in the pathogenesis of diabetic cardiovascular complications,
myocardial ischemia, and atherosclerosis (Lu and Mehta, 2011;
Yan et al., 2011; Xu et al., 2013b). Disturbance of LOX-1 mediated
signaling pathways has been proposed as a potential strategy for
the anti-atherosclerotic drug discovery (Sawamura et al., 1997;
Chen et al., 2002, 2007). Although a variety of cells, including
monocytes, dendritic cells, lymphocytes, eosinophils, mast cells
and smooth muscle cells, contribute to atherogenesis (Moore
et al., 2013), endothelial dysfunction is considered to be an early
marker and played important roles in the pathophysiology of
atherosclerosis (Davignon and Ganz, 2004). ROS, an important
second messenger, is linked to many vascular diseases including
atherosclerosis (Vara and Pula, 2014). NOX4 is an important
source of ROS in endothelial cells (Ray and Shah, 2005). However,
the role of NOX4 in atherosclerosis is controversial (Hu et al.,
2008; Zhao et al., 2014). Furthermore, the TLRs-NF-κB pathway
has been reported to participate in the anti-atherosclerotic effect
of several natural products such as quercetin, pycnogenol, and
procyanidins (Martinez-Micaelo et al., 2012; Luo et al., 2015;
Bhaskar et al., 2016).
Salvia miltiorrhiza Bunge (Danshen) is a famous medical
herb with a long history of clinical application for treating
cardiovascular diseases, cancer, and osteoporosis (Cao et al.,
2012; Chen et al., 2014; Guo et al., 2014). Its ingredients
have been widely explored since last century. Two groups of
ingredients, the hydrophilic phenolic acids and the lipophilic
tanshinones, have been identified as the main bioactive
components. Tanshinones are a group of abietane diterpenes
composed of four rings. Totally, more than 50 tanshinones
have been isolated and identified since 1934 (Fan et al., 2012).
However, only a few of them, such as tanshinone IIA (Xu
and Liu, 2013a) and cryptotanshinone (Chen et al., 2013),
have been widely investigated. DHT (Supplementary Figure
S2), a tanshinone isolated from Danshen, is structurally similar
to that of tanshinone IIA and cryptotanshinone. For a long
time, investigation to its bioactivities was mainly focused on
its cytotoxicity to a variety of tumor cells (Liu et al., 2015;
Wang et al., 2015). Although increasing evidence suggested
that DHT has beneficial potentials for the treatment of
cardiovascular diseases (Zhang et al., 2009; Liu et al., 2010),
FIGURE 1 | DHT inhibited LPS-induced LOX-1 expression. Cells were
pretreated with DHT (10 nM) for 1 h and then stimulated with LPS (5 µg/mL)
for 24 h, the LOX-1 mRNA (A), protein (B), and localization (C) were detected
by real-time PCR, western blotting and immunofluorescence (60×),
respectively. DHT, dihydrotanshinone I.
its anti-atherosclerotic effect, either in vivo or in vitro, has
not been fully established. Here, this effect was evaluated
with experimental atherosclerosis model in ApoE−/− mice
and HUVECs. Furthermore, the underlying mechanisms were
explored as well.
MATERIALS AND METHODS
Materials
DHT (purity ≥ 98% by HPLC analysis, a lipophilic diterpenes)
was purchased from Chengdu Herbpurify Co. Ltd. (Chendu,
China). Hoechst 33342, N-acetyl cysteine (NAC), DPI, Rot,
TTFA, AA, All, NDGA, LPS (Escherichia coli serotype 055:B5,
LPS), 5-(6)-carboxy-2′,7′-dichlorodihydrofluorescein diacetate
(DCFH2-DA), PDTC, 2,2-Diphenyl-1-picrylhydrazyl (DPPH)
and lucigenin were purchased from Sigma–Aldrich (St. Louis,
MO, USA). Lipofectamine TM2000, DHE and Amplex Red
were purchased from Life Technology (Grand Island, NY,
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FIGURE 2 | DHT inhibited LPS-induced LOX-1 expression via TLR4/MyD88. Cells were pretreated with DHT (10 nM) for 1 h and then stimulated by LPS
(5 µg/mL) for 24 h, expressions of TLR2, TLR4 and MyD88 were determined by western blotting (A). Cells were transfected with siRNAs for TLR4 (B) and MyD88
(C) and then stimulated with LPS (5 µg/mL) for 24 h and the LOX-1 expression were determined by western blotting (D,E). Cont, control; NC-siRNA, negative
control siRNA. DHT, dihydrotanshinone I; N.S, no significant differences.
USA). Antibodies for NOX4, p22-phox, TLR4, MyD88 were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Antibodies for NF-κB p65, GAPDH, and Histone H3
were purchased from Cell Signaling Technology (Beverly,
MA, USA). Anti-LOX-1 antibody was obtained from R&D
(Minneapolis, MN, USA). The BCA protein kits were purchased
from Thermo Fisher (Suwanee, GA, USA). Fraction-PREP Cell
Fractionation Kit was purchased from BioVision (Milpitas, CA,
USA). SiRNA for TLR4, MyD88, and NOX4 were purchased from
Gene Pharma Company (Shanghai, China). Primers and other
materials for real-time PCR were purchased from Sangon Biotech
(Haimen, China) and TaKaRa Bio Group (Shiga, Japan). DiI-
ox-LDL was purchased from Yiyuan Biotechnology (Guangzhou,
China).
Kits for TC, LDL-C, HDL-C, TG, MDA, GSH, and SOD
were obtained from Nanjing Jiancheng Bioengineering Research
Institute (Nanjing, China).
Cell Culture
Human umbilical vein endothelial cells were cultured in Vascular
Cell Basal Medium with Endothelial Cell Growth Kit-BBE at
37◦C in a humidified atmosphere of 5% CO2. Before passaging
cells, issue culture flasks, 96-well plates and 6-well plates were
pre-coated with 0.1% gelatin. All assays were conducted using low
cell passage cells (2–5 passages).
Human monocyte cell line (THP-1) obtained from ATCC
(no: TIB-202, Rockville, MA, USA) was cultured in RPMI 1640
medium containing 10% fetal calf serum, 2 mM glutamine,
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FIGURE 3 | DHT inhibited LPS-induced ROS, H2O2, and O•−2 production. ROS (A), H2O2 (B), and O
•−
2 (C) production were determined by DCFH2-DA,
Amplex Red and DHE respectively, after LPS (5 µg/mL) treatment for 1 h with or without DHT (10 nM) or NAC (5 mM) pretreatment for 1 h. Effect of DHT on DPPH
radical was determined in a cell-free system (D). DHT, dihydrotanshinone I; ROS, reactive oxygen species; NAC, N-acetyl cysteine.
100 U/mL penicillin, and 100 µg/mL streptomycin. Cells were
seeded at 37◦C in a humidified atmosphere of 5% CO2 and
95% air.
Animal Experiment
Male ApoE−/− mice (6–8 weeks old) on C57BL/6J background
and age-matched wild-type C57BL/6J controls were purchased
from Beijing HFK Bioscience Co., Ltd. (Beijing, China). Mice
were housed in SPF-grade animal facilities (Certificate no. SCXK
2014-0004) at Zunyi Medical College, with a 12 h light/dark cycle,
at 23◦C (±2◦C). All animal procedures follow the NIH guide for
the Care and Use of Laboratory Animals (NIH Publications No.
80-23, revised 1978), and approved by the Institutional Animal
Use and Care Committee of Zunyi Medical College. Starting from
6 weeks, the mice were fed with a HCD (54.35% raw grain, 20%
lard, 0.15% cholesterol, 15% sucrose, 0.5% Sodium Cholate, 10%
yolk powder) for 12 weeks. All ApoE−/− mice were dosed daily
via intragastric gavage with 10 and 25 mg kg−1 DHT dissolved
in 0.5% CMC-Na or administered 0.5% CMC-Na alone (vehicle
control) (n= 8 per group).
Immunofluorescence Assay
Cells (1 × 104 cells/well) were seeded on glass slides in 96-
well plates. After LPS treatment (Sigma–Aldrich, St. Louis, MO,
USA) (with or without DHT pretreatment), the slides were fixed
with 4% PFA for 30 min. Then the slides were permeabilized
with PBS-T (containing 0.1% Triton x-100 in PBS solution)
and blocked with PBS-B (containing 4% BSA in PBS solution).
After incubated with primary antibody (1:1000) and secondary
antibody (1:2000), cells were stained with Hoechst 33342 in dark
for 5 min. The protein location and expression were observed
with IN Cell Analyzer 2000 (GE Healthcare).
Detection of Reactive Oxygen Species,
Superoxide Anion (O•−2 ), and Hydrogen
Peroxide (H2O2)
The effect of DHT on LPS-induced O•−2 , H2O2, and ROS
production were measured by DHE, Amplex Red, and DCFH2-
DA, respectively. Briefly, after LPS treatment for 30 min, cells
were washed with PBS and incubated with DHE (10 µM),
Amplex Red (50 µM), or DCFH2-DA (10 µM) for 30 min in
the dark at 37◦C. Then, cells were washed with PBS for three
times and fluorescence density was measured by Spectra Max
M5 Microplate Reader (Molecular Devices, Sunnyvale, CA, USA)
or by a flow cytometry using a FACSCantoTM system (BD
Biosciences).
DPPH Assay
To evaluate the direct scavenging effect of DHT on free radicals
in cell-free system, the DPPH system was adapted. DHT (0.01–
1 µM, final concentration) was incubated with ethanol solution
of DPPH (5.0× 10−4 M). After thoroughly mixing, the solutions
were kept in the dark for 20 min and the absorbency was
measured at 517 nm.
Western Blotting
Treated HUVECs were washed twice with ice-cold PBS and
lysed with RIPA buffer supplemented with a protease cocktail
and phosphatase inhibitors. The cell lysates were separated using
8–12% SDS-PAGE and transferred onto PVDF membranes. After
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FIGURE 4 | DHT inhibited LPS-induced NOX4 dependent ROS generation. Cells were treated with LPS (5 µg/mL) with or without 1 h pretreatment with DPI
(1 µM), NDGA (10 µM), All (10 µM), Rot (20 µM), TTFA (10 µM) or AA (5 µM) and the ROS was determined (A). NOX4 expression and localization were determined
by western blotting (B) and immunofluorescence (C) (60×). P22phox expression was determined by western blotting (D). Cells were transfected with NOX4 siRNA,
NOX4 (E) and LOX-1 expression (F) were determined by western blotting. Cont, control group; DHT, dihydrotanshinone I; NC-siRNA, negative control siRNA; DPI,
diphenyleneiodonium chloride; NDGA, nordihydroguaiaretic acid; All, allopurinol; AA, antimycin A; Rot, rotenone; TTFA, 2-thenoyltrifluoroacetone.
blocked with 5% non-fat milk in TBST (20 mM Tris-HCl,
500 mM NaCl, and 0.1% Tween 20) at room temperature for
1 h, membranes were incubated with specific primary antibodies
and secondary antibodies. The protein-antibody complexes were
detected by ECL Advanced Western Blot detection Kit. The
intensity of the band was quantitated with Quantity One software
(Bio-Rad).
Preparation of Membrane, Cytoplasmic
and Nuclear Fractions
The cytoplasmic and membrane proteins were isolated using
Fraction-PREP cell fractionation kit (Biovision Inc., Milpitas, CA,
USA) according to the manufacturer’s instructions1.
SiRNA Transfection
Gene silencing experiment of TLR4, MyD88, and NOX4 with
siRNA was performed according to our previous report (Zhao
et al., 2014).
1http://www.biovision.com/
Real-Time RT-PCR
The mRNA expression of LOX-1 was determined with real-time
PCR as our previous report (Zhao et al., 2014).
DiI-ox-LDL Uptake
The DiI-ox-LDL uptake assay was performed according to our
previous study with minor revisions (Zhang et al., 2006). Cells
(1.0 × 104/well) in 96-well plate cultured for overnight were
pretreated with DHT, inhibitors, or anti-LOX-1 antibody for 1 h
and then co-treated with LPS for another 24 h. After incubated
with DiI-ox-LDL (1 µg/mL) for 1 h at 37◦C in the dark, the cells
were gently washed with PBS for three times to remove the free
DiI-ox-LDL and the ox-LDL uptake was measured with IN Cell
Analyzer 2000.
Monocyte-endothelial Cell Adhesion
Assay
After various treatments, HUVECs were co-incubated with THP-
1 cells labeled with Hoechst 33342 for 3 h in the dark at 37◦C. The
non-adherent THP-1 cells were washed gently with PBS. Images
Frontiers in Pharmacology | www.frontiersin.org 5 November 2016 | Volume 7 | Article 418
fphar-07-00418 November 4, 2016 Time: 17:55 # 6
Zhao et al. Dihydrotanshinone I Inhibited Atherosclerosis
FIGURE 5 | DHT inhibited LPS-induced LOX-1 expression via NF-κB. Cells were treated with LPS (5 µg/mL) for 24 h with or without pretreatment with DHT,
PDTC, or NOX4 siRNA and the expression of p65 (A), LOX-1 (B), and p65 (C) was detected by western blotting. DHT, dihydrotanshinone I; PDTC, pyrrolidine
dithiocarbamic acid.
were obtained under random fields of each well using IN Cell
Analyzer 2000.
Immunohistochemistry
Immunohistochemical analysis on aortic sinus was performed as
described previously in detail (Xu et al., 2011). Sections, 8 µm
thick, were used for immunohistochemical staining with LOX-1,
NOX4 and phosphorylated NF-κB p65 antibodies. Color reaction
was developed with diaminobenzidine.
Aorta Collection and Lesion Size
Evaluation
To evaluate plaque extension, frozen sections of the aortic
sinus (8 µm) were stained using Oil Red O, hematoxylin and
eosin (H&E), respectively. Related experiments were performed
following the method of Paigen et al. (1987).
Blood Parameters
Blood samples were collected from the orbit before the mice were
killed. Serum TC, LDL-C, HDL-C, and TG were measured using
standard enzymatic colorimetric assays. MDA, GSH, and SOD
were detected by commercial kits.
Statistical Analysis
Twenty four ApoE−/− mice were randomly allocated to groups
and equal group sizes were obtained (n = 8 per group). Data
were expressed as the means ± SD. The differences between
groups were analyzed using Prism 5.0 (Graph Pad Software
Inc, San Diego, CA, USA) and the statistical analysis was
performed by analysis of variance (one-way ANOVA) followed by
Student Newman–Keuls test. p < 0.05 is considered statistically
significant.
RESULTS
DHT Inhibited LPS-Induced LOX-1
Expression
Firstly, the cytotoxic effect of DHT on HUVECs was determined
by MTT assay. Results showed that DHT was cytotoxic to
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FIGURE 6 | DHT inhibited LPS-induced ox-LDL uptake and monocyte adhesion mediated by LOX-1. Cells were pretreated with DHT (10 nM), siNOX4,
PDTC (10 µM), or anti-LOX-1 Ab (10 µg/mL) for 1 h before LPS treatment for 24 h. Then cells were incubated with DiI-ox-LDL (5 µg/mL) and the ox-LDL uptake
was measured with an inverted fluorescent microscopy (20×) (A). Cells received same treatment and were co-incubated with Hoechst 33342 labeled THP-1 cells.
The attached THP-1 cells were visualized by an inverted fluorescent microscopy (20×) (B). DHT, dihydrotanshinone I; NC-siRNA, negative control siRNA; PDTC,
pyrrolidine dithiocarbamic acid.
HUVECs at 1 µM (Supplementary Figure S1). To minimize
the cytotoxic effect of DHT on cell viability, 10 nM DHT
was chosen for further study. Compared with untreated
HUVECs, 24 h stimulation with LPS induced significant
LOX-1 expression at both mRNA (Figure 1A) and protein
(Figure 1B) levels, which were dramatically inhibited by DHT
pretreatment. Furthermore, immunofluorescence results showed
that LPS-induced LOX-1 expression was mainly localized on the
membrane, which was significantly suppressed by DHT as well
(Figure 1C).
DHT Inhibited LPS-Induced LOX-1
Expression via TLR4/Myd88
Our previous study demonstrated that TLR4/MyD88 signal
pathway was involved in LPS-induced LOX-1 expression
in endothelial cells (Zhao et al., 2014). Here, LPS-induced
expression of TLR4 and MyD88 was obviously inhibited
by DHT (Figure 2A). Furthermore, silence of either
TLR4 or MyD88 did not affect the expression of LOX-
1 in the absence of LPS (Figures 2B–D). In addition,
the LPS-induced expression of LOX-1 was significantly
decreased in both TLR4 and MyD88 silenced cells
(Figure 2E).
DHT Inhibited LPS-Induced ROS
Generation
LOX-1 was reported to be upregulated by oxidative stress
in vascular smooth muscle cells (Sun and Chen, 2011) and
endothelial cells (Zhao et al., 2014). LPS treatment for 4 h
induced endothelial ROS generation as detected by DCFH2-
DA (Figure 3A). Amplex Red and DHE assay showed that the
generation of both H2O2 and O•−2 was also significantly increased
after LPS stimulation. DHT and NAC pretreatment dramatically
inhibited these increases (Figures 3B,C). However, no effect of
DHT on DPPH was observed (Figure 3D).
DHT Inhibited LPS-Induced LOX-1
Expression Through NOX4
LPS-induced ROS generation was significantly inhibited by DPI
while NDGA, allopurinol (All), Rot, TTFA, and AA showed no
obvious effect (Figure 4A). Furthermore, LPS increased NOX4
protein expression (Figure 4B) and membrane aggregation
(Figure 4C) which was also inhibited by DHT. LPS-induced
p22phox expression was suppressed by DHT (Figure 4D).
In addition, silence NOX4 (Figure 4E) dramatically inhibited
LPS-induced LOX-1 expression (Figure 4F) (Supplementary
Figure S3).
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FIGURE 7 | DHT ameliorated serum lipid profile and reduced atherosclerosis in ApoE−/− mice. The serum TG, TC, LDL-C, and HDL-C were measured by
colorimetric assays (A–D). Aortic sinus sections were stained with Oil Red O and H&E to detect plaque sizes (E) (40×) and necrotic core areas (F) respectively (40×).
DHT, dihydrotanshinone I; TC, total cholesterol; TG, triglycerides; LDL-C, LDL cholesterol; HDL-C, HDL- cholesterol; Nec, necrotic core area; WT, wild type;
ApoE−/−, apolipoprotein E-deficient; N.S, no significant differences.
DHT Inhibited LPS-Induced LOX-1
Expression by Suppressing NF-κB
Activation
NF-κB pathway plays an essential role in LPS-induced LOX-1
expression in HUVECs (Zhao et al., 2014). The NF-κB p65 in
the nuclear in response to LPS was significantly increased which
was remarkably suppressed by DHT treatment (Figure 5A).
Furthermore, LPS-induced LOX-1 expression was inhibited by
PDTC, a NF-κB inhibitor (Figure 5B). In addition, LPS-induced
p65 nuclear translocation was significantly suppressed by NOX4
siRNA (Figure 5C).
DHT Inhibited LPS-Induced Ox-LDL
Uptake Mediated by LOX-1
In the DiI-ox-LDL uptake assay, compared with untreated
cells, LPS stimulation resulted in increased intracellular red
fluorescence in stimulated endothelial cells suggesting the
increase of DiI-ox-LDL internalization (Figure 6A). This increase
was significantly reversed by pretreatment with DHT, NOX4
siRNA, PDTC, and anti-LOX-1 antibody.
DHT Inhibited LPS-Induced THP-1
Adhesion Mediated by LOX-1
We previously reported the potential role of LOX-1 in LPS-
mediated monocyte-endothelial cells adhesion (Zhao et al.,
2014). In present research, LPS treatment for 24 h significantly
increased THP-1 cell adhesion to endothelial cells, which was
also dramatically inhibited by DHT, NOX4 siRNA, PDTC, and
anti-LOX-1 antibody (Figure 6B).
DHT Ameliorated the Serum Lipid Profile
in ApoE−/− Mice
As shown in Figures 7A–C, compared with the WT mice, high-
fat diet induced dramatically increase in TG, TC, LDL-C, as
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FIGURE 8 | DHT reduced oxidative stress, inhibited LOX-1, NF-κB, and LOX-1 expression in ApoE−/− mice. Expression of LOX-1 (A), NOX4 (F), and
NF-κB p65 (G) in the aorta was detected by immunohistochemistry. The MDA, GSH and SOD levels were detected by kits (C–E). LOX-1 expression was detected
by immunofluorescence (B). DHT, dihydrotanshinone I; MDA, malondialdehyde; GSH, glutathione; SOD, superoxide dismutase; WT, wild type; ApoE−/−,
apolipoprotein E-deficient.
well as HDL-C in ApoE−/− mice. Low dosage of DHT mildly
decreased the lipid levels of TC and LDL-C but showed no effect
on TG while at high dosage DHT dramatically inhibited TG, TC,
and LDL-C. Both dosages of DHT showed no effect on HDL-C
(Figure 7D).
DHT Reduced Atherosclerotic Plaque
Development in ApoE−/− Mice
Histopathological studies had showed that an atherosclerotic
plaques (Oil red O-stained red area) was formed and obvious
necrotic core areas (H&E-stained area) were observed in
ApoE−/− mice. DHT administration significantly reduced
plaque sizes as well as shrank necrotic core areas. High dosage
showed more potent inhibitory effect (Figures 7E,F).
DHT Reduced Oxidative Stress in
ApoE−/− Mice
As shown in Figures 8C–E, there was a slight decrease of SOD
while nearly fivefolds decrease of GSH and twofolds increase of
MDA in ApoE−/− mice compared to WT mice. The decreased
SOD and GSH and the increased MDA levels in the serum were
significantly reversed by DHT administration.
Frontiers in Pharmacology | www.frontiersin.org 9 November 2016 | Volume 7 | Article 418
fphar-07-00418 November 4, 2016 Time: 17:55 # 10
Zhao et al. Dihydrotanshinone I Inhibited Atherosclerosis
FIGURE 9 | Schematic diagram illustrating the molecular mechanisms underlying the anti-atherosclerotic effects of DHT.
DHT Inhibited NOX4, NF-κB and LOX-1
Expression in ApoE−/− Mice
Immunohistochemistry showed that LOX-1 was expressed at low
level in aorta of WT mice but significantly increased in ApoE−/−
mice, which was dramatically decreased in DHT treated mice
(Figure 8A). LOX-1 was mainly expressed on the endothelial
cells, which was further confirmed by immunofluorescence
(Figure 8B). Furthermore, immunohistochemistry analysis of
aortic sinus showed that the expression of NOX4 and
phosphorylated NF-κB p65 were remarkably increased in
ApoE−/− mice, which were significantly inhibited by DHT as
well (Figures 8F,G).
DISCUSSION
Herb extracts and single compounds from Salvia miltiorrhiza,
Curcuma longa, Rheum undulatum, and Panax notoginseng,
have been reported to regulate multiple targets that involved
in the initiation and progress of atherosclerosis (Quiles
et al., 2002; Fan et al., 2012; Zeng et al., 2012). Here, we
showed that DHT isolated from Salvia miltiorrhiza Bunge
significantly attenuated atherosclerosis through regulating LOX-
1 expression both in vivo and in vitro. The main findings
of this study are: (1). DHT inhibited LPS-induced LOX-1
expression through TLR4/NOX4/NF-κB pathway in endothelial
cells. (2). DHT benefited atherosclerosis by inhibiting LOX-
1-mediated ox-LDL endocytosis and monocyte-endothelial
cells adhesion in endothelial cells. (3). DHT attenuated
atherosclerosis in ApoE−/− mice through regulating LOX-1
expression.
Our previous study demonstrated that LPS induced LOX-1
expression in a TLR4/MyD88-dependent manner (Zhao et al.,
2014). Here, we found that LPS-induced expression of TLR4
and MyD88 was dramatically inhibited by DHT. However, DHT
showed no effect on TLR2 expression. Furthermore, silencing
of TLR4 and MyD88 significantly reversed LPS-induced LOX-
1 expression. Thus, DHT might inhibit LPS-induced LOX-1
expression in a TLR4/MyD88 manner.
TLR4/MyD88 functions as the upstream of ROS (Zhang
et al., 2009). Cryptotanshinone, an analog of DHT, has been
reported to inhibit ox-LDL- or LPS- induced endothelial
ROS formation (Chen et al., 2008; Zhao et al., 2014).
In present study, DHT significantly inhibited LPS-induced
ROS production in endothelial cells. Further investigation
showed that DHT inhibited both LPS-induced O•−2 and H2O2
production but has no effect on DPPH free radical. Thus
suggested that DHT may not be a ROS scavenger. Since LPS-
induced ROS production was potentially inhibited by NDAPH
oxidase inhibitor DPI but not by LOX inhibitor NDGA, XO
inhibitor ALL, mitochondria respiratory electron-transport chain
inhibitors AA, TIFA and Rot, it suggested that NADPH oxidase
was the main source of ROS in response to LPS. Among
the 7 NADPH oxidase isoforms NOX4 was identified as the
main contributor for LPS-induced ROS in HUVECs (Mehta
et al., 2006; Park et al., 2006; Zhao et al., 2014). In our
study, DHT suppressed LPS-induced NOX4 expression and
membrane translocation. Previous studies showed that activated
TLR4/MyD88 upregulated NOX4 expression in LPS-activated
cells and lead to atherosclerosis (Patel et al., 2006; Petry et al.,
2006). Consistent with these findings, here we found that
silence TLR4 decreased NOX4 expression in response to LPS in
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endothelial cells (data not shown). Furthermore, DHT inhibited
LPS induced p22phox, an important NOX4 adaptor for NOX4
activation (Geiszt and Leto, 2004), expression. In addition, silence
NOX4 inhibited LPS-induced LOX-1 expression. Collectively,
these results suggested that DHT inhibited LPS-induced LOX-1
expression mediated by NOX4-dependent ROS.
The transcription factor NF-κB plays an essential role
in regulating of various inflammatory cytokines secretion
mediated by the intracellular ROS levels (Tak and Firestein,
2001). Increased nuclear translocation of NF-κB p65 by LPS
was inhibited by DHT and NOX4 siRNA. Increased LOX-1
expression was suppressed by PDTC, a NF-κB inhibitor. Thus,
NOX4 mediated the downregulation of LOX-1 expression by
DHT through NF-κB.
Ox-LDL uptake and monocyte-endothelial cells adhesion play
important roles in promoting atherosclerosis (Mestas and Ley,
2008; Di Pietro et al., 2016). Binding and endocytosis of ox-
LDL is considered the primary function of LOX-1 in endothelial
cells (Sawamura et al., 1997) and macrophages (Li et al., 2009).
LOX-1 also act as an important adhesion molecule leading
monocyte-endothelial cell adhesion (Honjo et al., 2003; Bai et al.,
2005). LPS-induced ox-LDL uptake and THP-1 cells adhesion
were inhibited by anti-LOX-1 antibody suggesting the key roles
of LOX-1. The inhibitory effect of NOX4 siRNA, PDTC, and
DHT provide evidence that DHT inhibited ox-LDL uptake and
monocyte adhesion by downregulating LOX-1.
To further confirm the anti-atherosclerotic effect of DHT,
a high fat diet induced atherosclerosis was established in
ApoE−/− mice. Imbalance of lipid profile, formation of
atherosclerotic plaque and occurrence of necrotic cores are
important characteristics of atherosclerosis (Ku et al., 1985;
Shahar et al., 2003; Cai et al., 2005). Oral administration of
DHT for 12 weeks dramatically decreased the serum levels
of TG, TC, and LDL-C suggesting that DHT might benefit
atherosclerosis by decreasing lipid levels. The decreased MDA
and increased SOD and GSH by DHT also suggested that it also
regulated oxidative stress in vivo. The reduction of atherosclerotic
plaque sizes and the shrinkage of necrotic core areas in DHT
treated ApoE−/− mice provides the direct evidence for its anti-
atherosclerotic effect. Furthermore, consistent with the in vitro
results, expression of LOX-1, NOX4, and NF-κB in the aorta was
also reduced by DHT. Thus, DHT showed anti-atherosclerotic
effect in animal model.
CONCLUSION
In summary, as depicted in Figure 9, this study showed
that natural product DHT inhibited NF-κB mediated LOX-1
expression both in vivo and in vitro through NOX4-derived ROS
generation. In view of the key roles of LOX-1 in the pathogenesis
of atherosclerosis, inhibition of LOX-1 contributed to the anti-
atherosclerotic effect of DHT.
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